The soluble decoy IL-1β receptor rilonacept and the neutralizing IL-1β antibody canakinumab have been used for the clinical treatment of cryopyrin-associated autoinflammatory syndrome (CAPS), which is caused by the NLRP3 mutation [33]. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.